Literature DB >> 26435964

An Experimental Study to Evaluate the Effect of Memantine in Animal Models of Anxiety in Swiss Albino Mice.

Harish G Bagewadi1, Afzal Khan Ak2, Rekha M Shivaramegowda2.   

Abstract

BACKGROUND: Due to the adverse effects produced by the present conventional medicines for anxiety disorders, research for newer drugs is still desirable. From the literature it is evident that NMDA receptors play a key role in animal models of anxiety. AIM: The present study is done to evaluate the antianxiety effect of memantine in swiss albino mice.
MATERIALS AND METHODS: The experimental study was conducted from November 2014 to January 2015. Animals were divided into four groups. Twelve mice were randomly allotted in each group. Animals in the first group received normal saline as a control 10ml/kg, lorazepam 0.5mg/kg was administered to second group, memantine 3mg/kg as a test drug was given to the third group and memantine 3mg/kg + lorazepam 0.5mg/kg was administered to the fourth group. All the drugs were given for 7 consecutive days by intraperitoneal route.
RESULTS: Results were analyzed by one-way ANOVA followed by Post-hoc Tukey's test. On the 1(st) day, memantine treated group did not show statistical significant anxiolytic effect in both the behavioural paradigms when compared to control group. On the 8(th) day, the animals showed significant decrease p<0.001 in step down latency period in shock free zone (185.4±3.87 Vs 278.3±5.49), significant increase p<0.001 in step down errors (6.8±0.78 Vs 1.4±0.19) and significant increase p<0.001 in total time spent in shock zone (32.1±2.22 Vs 5.6±0.6). In open field test, on 8(th) day the animals treated with memantine when compared to control group, showed significant increase p<0.001 in number of squares crossed (112.7± 2.69 Vs 83.2±2.96), time spent in central square (11.5±1.26 Vs 3.4±0.65), no. of rearings (32.4±2.61 Vs 17±1.81) and significant decrease p<0.001 in freezing time (15.2±1.12 Vs 20.2±2.29). Memantine showed synergistic antianxiety effect when combined with lorazepam.
CONCLUSION: Memantine showed significant anxiolytic effect in open field and passive avoidance response tests which are commonly used experimental models to assess anxiety states in animals.

Entities:  

Keywords:  Anti-anxiety; Lorazepam; Open field test; Passive avoidance test

Year:  2015        PMID: 26435964      PMCID: PMC4576556          DOI: 10.7860/JCDR/2015/13233.6287

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  42 in total

1.  Training chicks on a passive avoidance task modulates glutamate-stimulated inositol phosphate accumulation.

Authors:  S Bullock; S P Rose; B Pearce; J Potter
Journal:  Eur J Neurosci       Date:  1993-01-01       Impact factor: 3.386

2.  Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice.

Authors:  J L Wiley; A F Cristello; R L Balster
Journal:  Eur J Pharmacol       Date:  1995-12-27       Impact factor: 4.432

3.  NMDA receptor activation antagonizes the NMDA antagonist-induced antianxiety effect in the elevated plus-maze test in mice.

Authors:  Ewa Poleszak; Anna Serefko; Aleksandra Szopa; Sylwia Wośko; Jarosław Dudka; Andrzej Wróbel; Tomasz Oniszczuk; Piotr Wlaź
Journal:  Pharmacol Rep       Date:  2013       Impact factor: 3.024

4.  Effects of NMDA receptor antagonists on passive avoidance learning and retrieval in rats and mice.

Authors:  N Venable; P H Kelly
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 5.  Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion.

Authors:  Christopher Barkus; Stephen B McHugh; Rolf Sprengel; Peter H Seeburg; J Nicholas P Rawlins; David M Bannerman
Journal:  Eur J Pharmacol       Date:  2009-10-15       Impact factor: 4.432

6.  Effects of antagonists at the NMDA receptor complex in two models of anxiety.

Authors:  A Plaznik; W Palejko; M Nazar; M Jessa
Journal:  Eur Neuropsychopharmacol       Date:  1994-12       Impact factor: 4.600

Review 7.  Advances in the treatment of anxiety: targeting glutamate.

Authors:  Asher B Simon; Jack M Gorman
Journal:  NeuroRx       Date:  2006-01

8.  Effect of an NMDA receptor agonist on T-maze and passive avoidance test in 12-week streptozotocin-induced diabetic rats.

Authors:  Emilia Grzeda; Róza J Wiśniewska; Konstanty Wiśniewski
Journal:  Pharmacol Rep       Date:  2007 Nov-Dec       Impact factor: 3.024

9.  Involvement of NMDA receptor in low-frequency magnetic field-induced anxiety in mice.

Authors:  Balwant P Salunke; Sudhir N Umathe; Jagatpalsingh G Chavan
Journal:  Electromagn Biol Med       Date:  2013-10-16       Impact factor: 2.882

10.  Antidepressant efficacy screening of novel targets in the chick anxiety-depression model.

Authors:  Kenneth J Sufka; Jason E Warnick; Cassan N Pulaski; Stephen R Slauson; Young B Kim; John M Rimoldi
Journal:  Behav Pharmacol       Date:  2009-03       Impact factor: 2.293

View more
  3 in total

1.  Battery of behavioral tests in mice to study postoperative delirium.

Authors:  Mian Peng; Ce Zhang; Yuanlin Dong; Yiying Zhang; Harumasa Nakazawa; Masao Kaneki; Hui Zheng; Yuan Shen; Edward R Marcantonio; Zhongcong Xie
Journal:  Sci Rep       Date:  2016-07-20       Impact factor: 4.379

2.  Memantine Differentially Regulates Tau Phosphorylation Induced by Chronic Restraint Stress of Varying Duration in Mice.

Authors:  Yunsheng Liu; Lan Cao; Xiaoxu Zhang; Yan Liang; Yuxia Xu; Cuiqing Zhu
Journal:  Neural Plast       Date:  2019-02-14       Impact factor: 3.599

3.  The Multi-Targeting Ligand ST-2223 with Histamine H3 Receptor and Dopamine D2/D3 Receptor Antagonist Properties Mitigates Autism-Like Repetitive Behaviors and Brain Oxidative Stress in Mice.

Authors:  Nermin Eissa; Karthikkumar Venkatachalam; Petrilla Jayaprakash; Markus Falkenstein; Mariam Dubiel; Annika Frank; David Reiner-Link; Holger Stark; Bassem Sadek
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.